Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Emory University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
NRG Oncology
NRG Oncology
Alliance for Clinical Trials in Oncology
Alliance for Clinical Trials in Oncology
NRG Oncology
Ohio State University Comprehensive Cancer Center
OHSU Knight Cancer Institute
University of Southern California
Mayo Clinic
Ohio State University Comprehensive Cancer Center
M.D. Anderson Cancer Center
Emory University
Mayo Clinic
Ohio State University Comprehensive Cancer Center
Thomas Jefferson University
Roswell Park Cancer Institute
University of Southern California
Mayo Clinic
Emory University
University of Rochester
Mayo Clinic
Mayo Clinic
Vanderbilt-Ingram Cancer Center
Mayo Clinic
University of California, San Francisco
City of Hope Medical Center
Mayo Clinic
Mayo Clinic
Stanford University
Jonsson Comprehensive Cancer Center
Lipidica, a.s.
Emory University
City of Hope Medical Center